Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening-Reference-Cited by-同舟云学术

Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening

Published:2023-11 Issue: Volume:240 Page:115644
ISSN:0956-5663
Container-title:Biosensors and Bioelectronics
language:en
Short-container-title:Biosensors and Bioelectronics

Author:

Ratajczak Katarzyna,Grel Hubert,Olejnik Piotr,Jakiela Slawomir,Stobiecka Magdalena^ORCID

Funder

Fundacja na rzecz Nauki Polskiej

Narodowe Centrum Nauki

Publisher

Elsevier BV

Subject

Electrochemistry,Biomedical Engineering,General Medicine,Biophysics,Biotechnology

Reference127 articles.

1. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data;Aguiar;Immunotherapy,2017

2. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma;Ahmed;Expet Rev. Clin. Pharmacol.,2019

3. Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy;Ai;Drug Des. Dev. Ther.,2020

4. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics;Akinleye;J. Hematol. Oncol.,2019

5. FDA approval summary: pembrolizumab plus lenvatinib for endometrial carcinoma, a collaborative international review under project orbis;Arora;Clin. Cancer Res.,2020

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposome fusion assisted delivery of silica nanoquenchers for rapid detection of exosomal MicroRNAs;Sensors and Actuators B: Chemical;2024-09

2. Exploring novel circulating biomarkers for liver cancer through extracellular vesicle characterization with infrared spectroscopy and plasmonics;Analytica Chimica Acta;2024-08

3. Extracellular vesicle surface display of αPD‐L1 and αCD3 antibodies via engineered late domain‐based scaffold to activate T‐cell anti‐tumor immunity;Journal of Extracellular Vesicles;2024-07

4. The opportunities and challenges of using PD-1/PD-L1 inhibitors for leukemia treatment;Cancer Letters;2024-07

5. Recent advances in understanding the immune microenvironment in ovarian cancer;Frontiers in Immunology;2024-06-05